The Center for Public Integrity reports that three of the nation’s leading trade associations have a message for their member corporations: Resist activists who demand you disclose more details about your politicking than the law requires.
“Regulatory cooperation” is set to be at the heart of the Transatlantic Trade and Investment Partnership (TTIP), which is currently under negotiation between the European Union and the US. A new report from the Corporate Europe Observatory warns that the treaty will allow bureaucrats and big business to attack the public interest. The report looks at cases of regulatory cooperation between the US and the EU that have had a negative impact on regulations in the public interest. It illustrates that TTIP was born out of a dialogue between big business and trade officials, and as a result clearly reflects the enthusiasm of transnational corporations for regulatory issues.
Union of Concerned Scientists
UCS released a new report on scientific integrity at four federal agencies: US Centers for Disease Control and Prevention, Food and Drug Administration, Fish and Wildlife Service, and the National Oceanic and Atmospheric Administration. Almost a third (31%) of the 5,206 scientists who answered the survey reported that they thought business interests played too big a role in agency decisions.
Phineas Baxandall and Michelle Sukra
The United States Public Interest Research Group Education Fund released a report that examines which federal agencies allow companies to write off out-of-court settlements as tax deductions, and which are transparent about it. Here’s the Executive Summary.
Gilead Sciences executives were acutely aware in 2013 that their plan to charge an exorbitantly high price for a powerful new hepatitis C drug would spark public outrage, reports the Washington Post, but they pursued the profit-driven strategy anyway, according to a Senate Finance Committee investigation report released Tuesday.
Ellen R. Shaffer, Joseph E. Brenner Nov. 6, 2015 Cross-posted from CPATH
The vacuous “tobacco control” provision in the Trans Pacific Partnership (TPP) virtually capitulates to the demands of multinational tobacco corporations, jeopardizing nations’ health and economic welfare. Public health and medical advocates in the U.S. and abroad consistently urged negotiators to exclude tobacco control protections from trade challenges under the TPP. But tobacco industry opposition won the day, bolstered by corporate allies concerned that addressing the uniquely lethal effects of tobacco in trade agreements could set a precedent for reining in their own practices.
Reuters reports that leaders of India’s $15 billion pharmaceuticals industry, a major supplier of affordable generics to the world, have joined public health activists in criticizing a new U.S.-led trade deal they say will delay the arrival of new cheap drugs. Industry executives said provisions of the Trans-Pacific Partnership (TPP) deal struck earlier this month between 12 nations that shield new drug data from competitors would hurt their business in those nations.